BOSTON, June 13, 2025 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it entered into an agreement granting Macrocyclics Inc. (Macrocyclics) exclusive manufacturing and distribution rights to Ratio’s proprietary chelator MacropaTM enabling broad access worldwide. Macropa is a proprietary, best-in-class, bifunctional… Read more

BOSTON, May 8, 2025 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced that it entered into an agreement with the Medical Innovation Technology Management division of Wasatch Group to partner and construct a state-of-the-art radiopharmaceutical research and manufacturing facility in Salt Lake… Read more

Ratio to to receive upfront, and potential milestones and tiered royalty payments BOSTON, November 18, 2024 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE:… Read more

BOSTON, June 20, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Former U.S. Senator William “Mo” Cowan to its Board of Directors. Senator Cowan brings a wealth of experience in government, law, healthcare, and public policy… Read more

BOSTON, May 6, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Marc Becker as the company’s Chief Financial Officer and Chief Operating Officer. This appointment will reinforce Ratio’s financial and operational leadership by bringing significant experience… Read more

BOSTON, April 2, 2024 – Ratio Therapeutics Inc. (Ratio), an emerging pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointments of Bill Cupelo as the company’s Chief Business Officer and D. Scott Holbrook, MS, FSNMMI-TS to its Board of Directors. These strategic additions to Ratio’s leadership… Read more